These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 11711002)

  • 61. How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
    Phillips PS
    Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):130-1. PubMed ID: 16265453
    [No Abstract]   [Full Text] [Related]  

  • 62. Cholesterol reduction in patients with lower limb atherosclerotic disease.
    Bismuth J; Kofoed SC; Sillesen HH
    Dan Med Bull; 2002 Feb; 49(1):61-4. PubMed ID: 11894724
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lipid-lowering therapy and risk of coronary events.
    Mascitelli L; Pezzetta F
    JAMA; 2003 Apr 23-30; 289(16):2071; author reply 2071-2. PubMed ID: 12709464
    [No Abstract]   [Full Text] [Related]  

  • 65. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania PC;
    Am Heart J; 2004 Dec; 148(6):1053-9. PubMed ID: 15632893
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States.
    Woloshin S; Schwartz LM; Kerin K; Welch HG
    J Gen Intern Med; 2007 Feb; 22(2):197-204. PubMed ID: 17356986
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reassessment of the value of lowering serum cholesterol. Questioning the wisdom of widespread intervention.
    Labreche DG
    Clin Pharm; 1988 Aug; 7(8):592-603. PubMed ID: 3048850
    [No Abstract]   [Full Text] [Related]  

  • 68. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    Margolis KL; Davis BR; Baimbridge C; Ciocon JO; Cuyjet AB; Dart RA; Einhorn PT; Ford CE; Gordon D; Hartney TJ; Julian Haywood L; Holtzman J; Mathis DE; Oparil S; Probstfield JL; Simpson LM; Stokes JD; Wiegmann TB; Williamson JD;
    J Clin Hypertens (Greenwich); 2013 Aug; 15(8):542-54. PubMed ID: 23889716
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease.
    Ito MK; Shabetai R
    Am J Cardiol; 1997 Sep; 80(6):799-802. PubMed ID: 9315597
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program.
    Grundy SM; Cleeman JI; Rifkind BM; Kuller LH
    Arch Intern Med; 1999 Aug 9-23; 159(15):1670-8. PubMed ID: 10448768
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Cholesterol--the main risk factor in ischemic heart disease].
    Heyden S; Kroos S
    Schweiz Rundsch Med Prax; 1988 Nov; 77(48):1312-7. PubMed ID: 3064242
    [No Abstract]   [Full Text] [Related]  

  • 72. Decrease in all-cause and CHD mortality with pravastatin over a broad range of initial cholesterol levels.
    Goodwin L
    J Insur Med; 1998; 30(4):276-7. PubMed ID: 10537938
    [No Abstract]   [Full Text] [Related]  

  • 73. [Are statins indicated in the prevention of cerebral infarct?].
    Díez-Tejedor E; Egido Herrero JA; Gil Núñez AC; González-Juanatey JR; López Pastor A; Moreno JM; Moltó Jordà JM; Mostaza Prieto JM; Matías-Guiu J
    Rev Neurol; 2000 Apr 1-15; 30(7):671-93. PubMed ID: 10859749
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bridging the treatment gap.
    Smith SC
    Am J Cardiol; 2000 Jun; 85(12A):3E-7E. PubMed ID: 10858487
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PRINCE's prospects: statins, inflammation, and coronary risk.
    Azar RR; Waters DD
    Am Heart J; 2001 Jun; 141(6):881-3. PubMed ID: 11376298
    [No Abstract]   [Full Text] [Related]  

  • 76. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group.
    Am J Cardiol; 1997 Mar; 79(6):756-62. PubMed ID: 9070554
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Does cholesterol lowering prevent stroke?
    Henry RY; Kendall MJ
    J Clin Pharm Ther; 1998 Oct; 23(5):337-44. PubMed ID: 9875681
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of pravastatin on coronary events after myocardial infarction.
    Auerbach I; Behar S; Motro M
    N Engl J Med; 1997 Mar; 336(13):962. PubMed ID: 9072702
    [No Abstract]   [Full Text] [Related]  

  • 79. Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate.
    Pharoah P
    BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9553009
    [No Abstract]   [Full Text] [Related]  

  • 80. Broader use of lipid-lowering therapy argued.
    Johnson RA
    Clin Cornerstone; 1999; 1(6):57-8. PubMed ID: 10682190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.